Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Rating) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. […]
Relay Therapeutics (NASDAQ:RLAY – Get Rating) had its price objective cut by Barclays from $23.00 to $15.00 in a report published on Wednesday morning, The Fly reports. They currently have an equal weight rating on the stock. Several other brokerages have also commented on RLAY. Oppenheimer started coverage on shares of Relay Therapeutics in a […]
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Rating) saw unusually large options trading activity on Tuesday. Investors purchased 5,490 call options on the company. This represents an increase of 1,083% compared to the average volume of 464 call options. Insider Transactions at Relay Therapeutics In other news, CEO Sanjiv Patel sold 14,000 shares of the company’s […]
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Rating) traded up 4.1% during trading on Thursday . The stock traded as high as $12.95 and last traded at $12.86. 767,208 shares were traded during mid-day trading, a decline of 50% from the average session volume of 1,528,316 shares. The stock had previously closed at $12.35. […]
Monarch Partners Asset Management LLC grew its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Rating) by 100.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 85,139 shares of the company’s stock after buying an additional 42,579 shares during the […]